ROS1 and Miyoshi myopathy: The RNA-seq-based risk scores were significantly higher in the MM patients and were characterized by more ASXL1, ATM, BRAF, DIS3, EP300, FGFR3, KMT2B, LRP1B, MAP3K1, MAX, NOTCH2, NUP214, PRDM1, PTPRD, RB1, ROS1, SETD2, TP53, TRRAP, and ZFHX3 mutations compared to the unmutated MM patients (Figure 3B).